Fate Therapeutics Inc. diskutieren
Fate Therapeutics Inc.
WKN: A1W50M / Symbol: FATE / Name: Fate / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,93 €
3,45 %
Buy Fate Therapeutics Inc.
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $10.00 price target on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Mizuho from $12.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Barclays PLC from $6.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Bank of America Co. from $2.00 to $6.00. They now have an "underperform" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $4.00.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Barclays PLC from $10.00 to $2.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Neueste Beiträge
National_Bankshares_ in Bank of Montreal diskutieren